Bio-Thera Solutions Ltd - Asset Resilience Ratio
Bio-Thera Solutions Ltd (688177) has an Asset Resilience Ratio of 4.09% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bio-Thera Solutions Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Bio-Thera Solutions Ltd's Asset Resilience Ratio has changed over time. See Bio-Thera Solutions Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bio-Thera Solutions Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Bio-Thera Solutions Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥90.22 Million | 4.09% |
| Total Liquid Assets | CN¥90.22 Million | 4.09% |
Asset Resilience Insights
- Limited Liquidity: Bio-Thera Solutions Ltd maintains only 4.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bio-Thera Solutions Ltd Industry Peers by Asset Resilience Ratio
Compare Bio-Thera Solutions Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Bio-Thera Solutions Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Bio-Thera Solutions Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.09% | CN¥90.22 Million ≈ $13.20 Million |
CN¥2.21 Billion ≈ $322.74 Million |
-10.38pp |
| 2023-12-31 | 14.47% | CN¥331.03 Million ≈ $48.44 Million |
CN¥2.29 Billion ≈ $334.67 Million |
-14.42pp |
| 2022-12-31 | 28.90% | CN¥629.89 Million ≈ $92.17 Million |
CN¥2.18 Billion ≈ $318.96 Million |
+5.87pp |
| 2021-12-31 | 23.03% | CN¥602.83 Million ≈ $88.21 Million |
CN¥2.62 Billion ≈ $383.06 Million |
-16.91pp |
| 2020-12-31 | 39.94% | CN¥955.77 Million ≈ $139.86 Million |
CN¥2.39 Billion ≈ $350.19 Million |
-- |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more